Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted) (2019 - 2025)

Allogene Therapeutics' EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.19 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 40.63% year-over-year to -$0.19; the TTM value through Sep 2025 reached -$0.97, up 37.82%, while the annual FY2024 figure was -$1.32, 36.84% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.19 at Allogene Therapeutics, up from -$0.23 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.01 in Q4 2021 and bottomed at -$0.69 in Q1 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.38 (2024), against an average of -$0.41.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 100.93% in 2021 before it crashed 6600.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.01 in 2021, then plummeted by 6600.0% to -$0.65 in 2022, then increased by 21.54% to -$0.51 in 2023, then soared by 47.06% to -$0.27 in 2024, then grew by 29.63% to -$0.19 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's EPS (Weighted Average and Diluted) are -$0.19 (Q3 2025), -$0.23 (Q2 2025), and -$0.28 (Q1 2025).